ARTICLE SUMMARY:
The 2020 launch of the RADx program has resulted in an unprecedented influx of funding and attention into the diagnostics industry, which has led to technological innovation and business shifts that affect far more than COVID-19 treatment.
Through much of the pandemic, diagnostic testing faced enormous challenges, including lack of understanding of clinical utility, scaling operations, distribution, and supply chain issues. In April 2020, the NIH set up the Rapid Acceleration of Diagnostics (RADx) program, which leverages expertise from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) and other government agencies to speed development, validation, and commercialization of point-of-care and home tests and improve clinical laboratory detection of SARS-CoV-2.
